Fig. 3: Forest plot of efficacy outcomes by PD-L1 CPS with nivolumab plus chemotherapy versus chemotherapy.
From: Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
a, Overall survival. PD-L1 CPS expression indeterminate, not evaluable or not reported for n = 19 patients. Data are presented as unstratified hazard ratios and 95% confidence interval. b, Objective response rate among randomized patients who had target lesion measurements at baseline, per blinded independent central review assessment. PD-L1 CPS expression indeterminate, not evaluable or not reported for n = 14 patients; percentages may not reflect an exact difference, owing to rounding. Data are presented as unweighted ORR differences and 95% confidence interval.
